WHO Sounds Warning Over Acute Shortage of Obesity Injections

Less than one in 10 patients who could benefit from weight-loss injections like Wegovy are able to get them, caution the World Health Organization as it releases its initial advice on the therapies.

Given over a billion individuals worldwide currently living with obesity, it is calling for increased and just availability to these injectable treatments.

According to forecasts, over two billion will be obese by 2030 without intervention.

"The latest guidance acknowledges that excess weight is a long-term condition that can be addressed with holistic and ongoing support," remarked its chief Tedros Adhanom Ghebreyesus.

Substantial prices, insufficient output, and supply-chain constraints are key obstacles to universal availability to the jabs that can assist patients in reducing considerable body mass, notes the body.

Skinny Jab Scarcity

Even under the present most favorable scenario, the production of such drugs would only suffice for approximately 100 million people – under 10% of eligible patients, per the WHO.

The recommendation urges governments and firms to expand availability, through approaches like voluntary licensing.

A patent on the active ingredient – the core component of a leading brand – is scheduled to end in a number of countries in 2026.

How Obesity Jabs Operate

These medications imitate a biological compound to slow digestion, suppress the appetite and boost the sense of being full so individuals consume fewer calories.

Patients commonly see weight reduction within a few weeks of starting on the once-weekly jabs.

Studies indicates people may see weight return after a year of halting the drug, when their typical food cravings come back.

Being carrying excess weight elevates your likelihood for developing medical conditions, like diabetes, heart disease, brain attack, and specific cancers.

Excess weight affects people in every country and was linked to 3.7 million fatalities worldwide in 2024, according to the WHO.